Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease

Bulck, M. V., Sierra‐Magro, A., Alarcón-Gil, J., Pérez‐Castillo, A., & Morales-Garcia, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030719 · Cited by 186

Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease

Magalingam, K. B., Radhakrishnan, A., Ping, N. S., & Haleagrahara, N. (2018) · BioMed Research International · doi:10.1155/2018/3740461 · Cited by 178

Inflammation, Infectious Triggers, and Parkinson's Disease

Caggiu, E., Arru, G., Hosseiniporgham, S., Niegowska, M., Sechi, G., Zarbo, I. R., & Sechi, L. A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00122 · Cited by 180

Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson’s Disease

Venkateshappa, C., Harish, G., Mythri, R. B., Mahadevan, A., Bharath, M. M. S., & Shankar, S. K. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0619-7 · Cited by 177

The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases

DeMaio, A., Mehrotra, S., Sambamurti, K., & Husain, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02605-9 · Cited by 192

Macrophages with cellular backpacks for targeted drug delivery to the brain

Klyachko, N. L., Polak, R., Haney, M. J., Zhao, Y., Neto, R. J. G., Hill, M. C., Kabanov, A. V., Cohen, R. E., Rubner, M. F., & Batrakova, E. V. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.06.017 · Cited by 176

The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes?

Copas, A. N. M., McComish, S. F., Fletcher, J. M., & Caldwell, M. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.666737 · Cited by 186

The NAD‐dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation

Pais, T. F., Szegő, É. M., Marques, O., Miller‐Fleming, L., Antas, P., Guerreiro, P. S., de Oliveira, R. M., Kasapoğlu, B., & Outeiro, T. F. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.200 · Cited by 177

Baicalein Attenuates Neuroinflammation by Inhibiting NLRP3/Caspase-1/GSDMD Pathway in MPTP-Induced Mice Model of Parkinson’s Disease

Rui, W., Li, S., Xiao, H., Xiao, M., & Shi, J. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa060 · Cited by 176

Periodontal microorganisms and Alzheimer disease – A causative relationship?

Jungbauer, G., Stähli, A., Zhu, X., Auber Alberi, L., Sculean, A., & Eick, S. (2022) · Periodontology 2000 · doi:10.1111/prd.12429 · Cited by 174

Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer’s disease

Sly, L. M., KRZESICKI, R. F., Brashler, J. R., Buhl, A.-L., McKinley, D. D., Carter, D. B., & Chin, J. E. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00730-4 · Cited by 180

Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein

Béraud, D., Hathaway, H. A., Trecki, J., Chasovskikh, S., Johnson, D. A., Johnson, J. A., Federoff, H. J., Shimoji, M., Mhyre, T. R., & Maguire‐Zeiss, K. A. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9401-0 · Cited by 179

Activation of the CB2 receptor system reverses amyloid-induced memory deficiency

Wu, J., Bie, B., Yang, H., Xu, J. J., Brown, D. L., & Naguib, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.011 · Cited by 180

Microglial Activation Parallels System Degeneration in Multiple System Atrophy

Ishizawa, K., Komori, T., Sasaki, S., Arai, N., Mizutani, T., & Hirose, T. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.1.43 · Cited by 172

The relation between α-synuclein and microglia in Parkinson’s disease: Recent developments

Sánchez-Guajardo, V., Tentillier, N., & Romero‐Ramos, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.02.008 · Cited by 178

Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.

Widner, B., Leblhuber, F., & Fuchs, D. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200014 · Cited by 171

Inflammation, the complement system and the diseases of aging

McGeer, E. G., Klegeris, A., & McGeer, P. L. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.008 · Cited by 170

Intercellular (Mis)communication in Neurodegenerative Disease

Garden, G. A., & Spada, A. R. L. (2012) · Neuron · doi:10.1016/j.neuron.2012.02.017 · Cited by 176

Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia

Peng, G.-S., Li, G., Tzeng, N., Chen, P.-S., Chuang, D., Hsu, Y., Yang, S., & Hong, J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.10.021 · Cited by 169

Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?

Serrano-Castro, P. J., Estivill‐Torrús, G., Cabezudo‐García, P., Bueno, J. A. R., Ciano-Petersen, N. L., Aguilar-Castillo, M. J., Suárez-Pérez, J., Jiménez-Hernández, M. D., Moya-Molina, M. Á., Oliver‐Martos, B., et al. (2020) · Neurología · doi:10.1016/j.nrl.2020.04.002 · Cited by 172

Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies

Ji, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., Zhang, M.-R., Suzuki, K., Ando, K., Staufenbiel, M., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2312-08.2008 · Cited by 169

Microglial response to 6-hydroxydopamine-induced substantia nigra lesions

Akiyama, H., & McGeer, P. L. (1989) · Brain Research · doi:10.1016/0006-8993(89)90857-3 · Cited by 169

Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity

Zheng, L. T., Ock, J., Kwon, B., & Suk, K. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2007.12.012 · Cited by 168

The role of inflammation in sporadic and familial Parkinson’s disease

Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 169

Systemic Infusion of Naloxone Reduces Degeneration of Rat Substantia Nigral Dopaminergic Neurons Induced by Intranigral Injection of Lipopolysaccharide

Liu, B., Jiang, J., Wilson, B. C., Du, L., Yang, S., Wang, J., Wu, G.-C., Cao, X.-D., & Hong, J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38877-9 · Cited by 167

Copper induces microglia-mediated neuroinflammation through ROS/NF-κB pathway and mitophagy disorder

Zhou, Q., Zhang, Y., Lu, L., Zhang, H., Zhao, C., Pu, Y., & Yin, L. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113369 · Cited by 172

Innate immune activation in neurodegenerative diseases

Castro‐Gomez, S., & Heneka, M. T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.010 · Cited by 176

Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid

Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & Bruijn, C. D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 169

Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease

Mogi, M., Harada, M., Kondo, T., Narabayashi, H., Riederer, P. F., & Nagatsu, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11686-q · Cited by 166

Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease

McNaught, K. S. P., & Olanow, C. W. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.08.012 · Cited by 166

Doxycycline Suppresses Microglial Activation by Inhibiting the P38 MAPK and NF-KB Signaling Pathways

Santa-Cecília, F. V., Socias, B., Ouidja, M. O., Sepulveda-Diaz, J. E., Acuña, L., Silva, R. L., Michel, P. P., Del-Bel, E., Cunha, T. M., & Raisman-Vozari, R. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9592-2 · Cited by 165

Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38

Xie, Z., Smith, C. J., & Eldik, L. J. V. (2003) · Glia · doi:10.1002/glia.10314 · Cited by 164

Biological links between traumatic brain injury and Parkinson’s disease

Delic, V., Beck, K. D., Pang, K. C. H., & Citron, B. A. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00924-7 · Cited by 165

Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease

Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., et al. (2013) · Scientific Reports · doi:10.1038/srep01393 · Cited by 164

Microglial Activation in Alzheimer Disease: Association with APOE Genotype

Egensperger, R., Kösel, S., von Eitzen, U., & Graeber, M. B. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00166.x · Cited by 164

Neural and Immune Mechanisms in the Pathogenesis of Parkinson’s Disease

Blandini, F. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9435-y · Cited by 165

The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease

Giulian, D., Haverkamp, L. J., Yu, J., Karshin, W. L., Tom, D., Li, J., Kazanskaia, A., Kirkpatrick, J. B., & Roher, A. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29719 · Cited by 161

Inflammation, Neurodegenerative Diseases, and Environmental Exposures

Campbell, A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.008 · Cited by 166

Parkinson's disease mortality and the industrial use of heavy metals in Michigan

Rybicki, B. A., Johnson, C. C., Uman, J. E., & Gorell, J. M. (1993) · Movement Disorders · doi:10.1002/mds.870080116 · Cited by 163

Novel tactics for neuroprotection in Parkinson's disease: role of antibiotics, polyphenols and neuropeptides

Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162

Inhibition of MMP‐3 or ‐9 suppresses lipopolysaccharide‐induced expression of proinflammatory cytokines and iNOS in microglia

Woo, M., Park, J., Choi, I., Kim, W., & Kim, H. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05430.x · Cited by 160

Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts

Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162

Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases

Cruz-Haces, M., TANG, J. C. Y., Acosta, G., Fernandez, J., & Shi, R. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0088-2 · Cited by 166

Oxidative Stress and Microglial Cells in Parkinson's Disease

Peterson, L. J., & Flood, P. M. (2012) · Mediators of Inflammation · doi:10.1155/2012/401264 · Cited by 167

Microglial PHOX and Mac‐1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha‐synuclein

Zhang, W., Dallas, S., Zhang, D., Guo, J., Pang, H., Wilson, B. C., Miller, D. S., Chen, B., Zhang, W., McGeer, P. L., et al. (2007) · Glia · doi:10.1002/glia.20532 · Cited by 166

Increased Immune Activation by Pathologic α‐Synuclein in Parkinson's Disease

Grozdanov, V., Bousset, L., Hoffmeister, M., Bliederhaeuser, C., Meier, C., Madiona, K., Pieri, L., Kiechle, M., McLean, P. J., Kassubek, J., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25557 · Cited by 161

Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease

Ebert, A. D., Beres, A. J., Barber, A. E., & Svendsen, C. N. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.09.022 · Cited by 161

Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms

Yu, L., Shen, H., Coelho, J. E., Araújo, I. M., Huang, Q., Day, Y., Rebola, N., Canas, P. M., Rapp, E. K., Ferrara, J., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21313 · Cited by 170

Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease

Curry, D. W., Stutz, B., Andrews, Z. B., & Elsworth, J. D. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171296 · Cited by 160

Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally

Ling, Z., Zhu, Y., Tong, C. W., Snyder, J. A., Lipton, J. W., & Carvey, P. M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.010 · Cited by 160

Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra

Feng, Z.-H., Wang, T.-G., Li, D.-D., Fung, P. C. W., Wilson, B. C., Liu, B., Ali, S. F., Langenbach, R. J., & Hong, J. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00704-8 · Cited by 160

Major histocompatibility complex antigen expression on rat microglia following epidural kainic acid lesions

Akiyama, H., Itagaki, S., & McGeer, P. L. (1988) · Journal of Neuroscience Research · doi:10.1002/jnr.490200202 · Cited by 160

Lactobacillus Plantarum PS128 Alleviates Neurodegenerative Progression in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mouse Models of Parkinson’s Disease

Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159

Exosomes and stem cells in degenerative disease diagnosis and therapy

Chang, Y.-H., Wu, K.-C., Harn, H.-J., Lin, S.-Z., & Ding, D.-C. (2018) · Cell Transplantation · doi:10.1177/0963689717723636 · Cited by 159

Neuroprotective and Anti-inflammatory Activities of Ketogenic Diet on MPTP-induced Neurotoxicity

Yang, X., & Cheng, B. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9336-y · Cited by 159

Manganese Induces Dopaminergic Neurodegeneration via Microglial Activation in a Rat Model of Manganism

Zhao, F., Cai, T., Liu, M., Zheng, G., Luo, W., & Chen, J. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn213 · Cited by 157

Microglia activation states and cannabinoid system: Therapeutic implications

Mecha, M., Carrillo-Salinas, F. J., Feliú, A., Mestre, L., & Guaza, C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.011 · Cited by 165

Glial phagocytic clearance in Parkinson’s disease

Tremblay, M.-E., Cookson, M. R., & Civiero, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0314-8 · Cited by 152

Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease

Pisani, V., Stefani, A., Pierantozzi, M., Natoli, S., Stanzione, P., Franciotta, D., & Pisani, A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-188 · Cited by 158

From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue

Tucker, D., Lu, Y., & Zhang, Q. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0712-2 · Cited by 162

Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s disease

Karayel, Ö., Winter, S. V., Padmanabhan, S., Kuras, Y. I., Vu, D. T., Tuncali, I., Merchant, K., Wills, A.-M. A., Scherzer, C. R., & Mann, M. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100661 · Cited by 161

Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses

Lofrumento, D. D., Nicolardi, G., Cianciulli, A., Nuccio, F. D., Pesa, V. L., Carofiglio, V. E., Dragone, T., Calvello, R., & Panaro, M. A. (2013) · Innate Immunity · doi:10.1177/1753425913488429 · Cited by 156

Parkinson's disease and cancer: two wars, one front

Devine, M. J., Plun‐Favreau, H., & Wood, N. W. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3150 · Cited by 155

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders

Hall, S., Janelidze, S., Surova, Y., Widner, H., Zetterberg, H., & Hansson, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-31517-z · Cited by 157

Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS)

Zhang, R., Gascon, R., Miller, R. G., Gelinas, D. F., Mass, J., Hadlock, K. G., Jin, X., Reis, J., Narvaez, A., & McGrath, M. S. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.10.009 · Cited by 158

CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease

Zhang, S., Wang, X.-J., Tian, L.-P., Pan, J., Lu, G.-Q., Zhang, Y.-J., Ding, J.-Q., & Chen, S.-D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-154 · Cited by 154

Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase

Li, Q., Xu, Z., Zhang, W., Wilson, B. C., Hong, J., & Flood, P. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-23 · Cited by 153

Microglia-Specific Metabolic Changes in Neurodegeneration

Aldana, B. I. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.03.006 · Cited by 158

Oxidative Stress and Parkinson's Diseasea

Owen, A., Schapira, A. H. V., Jenner, P. G., & MARSDEN, C. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb39064.x · Cited by 154

Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease

Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu103 · Cited by 153

Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases

Sokolova, E., & Reiser, G. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-03-0131 · Cited by 153

Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice

Sugama, S., Yang, L., Cho, B. P., DeGiorgio, L. A., Lorenzl, S., Albers, D. S., Beal, M. F., Volpe, B. T., & Joh, T. H. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04085-4 · Cited by 153

Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat

Walsh, S. R., Finn, D. P., & Dowd, E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.005 · Cited by 152

Primary Phagocytosis of Neurons by Inflamed Microglia: Potential Roles in Neurodegeneration

Neher, J. J., Neniškytė, U., & Brown, G. C. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00027 · Cited by 157

Beneficial Effects of Flavonoids Against Parkinson's Disease

Jung, U. J., & Kim, S. R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4078 · Cited by 150

Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

AlDakheel, A., Kalia, L. V., & Lang, A. E. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0218-1 · Cited by 164

Evidence of Inflammatory System Involvement in Parkinson’s Disease

Chao, Y., Wong, S. C., & Tan, E. K. (2014) · BioMed Research International · doi:10.1155/2014/308654 · Cited by 152

Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms

Ren, X., & Chen, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.602697 · Cited by 167

Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease

Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, M. F., & Lu, B. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-109 · Cited by 151

Parkinson’s Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation

Dutta, S., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L. E., & Nair, P. P. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19044 · Cited by 150

Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra

Arimoto, T., Choi, D., Lü, X., Liu, M., Nguyen, X. V., Zheng, N., Stewart, C. A., Kim, H., & Bing, G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.04.011 · Cited by 149

Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease

Gao, H., Liu, B., Zhang, W., & Hong, J. (2003) · The FASEB Journal · doi:10.1096/fj.03-0203fje · Cited by 149

The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease

Akıl, E., Bulut, A., Kaplan, İ., Özdemir, H. H., Arslan, D., & Aluçlu, M. U. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1976-1 · Cited by 148

The role of neuroinflammation on the pathogenesis of Parkinson's disease

Chung, Y. C., Ko, H. W., Bok, E., Park, E. S., Huh, S. H., Nam, J. H., & Jin, B. K. (2010) · BMB Reports · doi:10.5483/bmbrep.2010.43.4.225 · Cited by 149

Dopaminergic neurons degenerate by apoptosis in Parkinson's disease

Hirsch, É. C., Hunot, S., Faucheux, B. A., Agid, Y., Mizuno, Y., Mochizuki, H., Tatton, W. G., Tatton, N. A., & Olanow, W. C. (1999) · Movement Disorders · doi:10.1002/1531-8257(199903)14:2 · Cited by 152

Anti-apoptotic and Anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's Rat model

Shrivastava, P., Vaibhav, K., Tabassum, R., Khan, A., Ishrat, T., Khan, M. M., Ahmad, A., Islam, F., Safhi, M. M., & Islam, F. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.03.018 · Cited by 146

Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats

Kao, T.-K., Ou, Y., Kuo, J.-S., Chen, W., Liao, S., Wu, C.-W., Chen, C., Ling, N.-N., Zhang, Y., & Peng, W. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.10.008 · Cited by 147

Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood

Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V., & Link, H. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb02699.x · Cited by 147

Blood–brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons

Rite, I., Machado, A., Cano, J., & Venero, J. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04567.x · Cited by 147

Evaluation of Markers of Oxidative Stress, Antioxidant Function and Astrocytic Proliferation in the Striatum and Frontal Cortex of Parkinson’s Disease Brains

Mythri, R. B., Venkateshappa, C., Harish, G., Mahadevan, A., Muthane, U. B., Yasha, T. C., Bharath, M. M. S., & Shankar, S. K. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0471-9 · Cited by 148

PPAR: a therapeutic target in Parkinson’s disease

Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 151

Parkinson’s disease and enhanced inflammatory response

Stojkovska, I., Wagner, B. M., & Morrison, B. E. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215576313 · Cited by 149

Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.

Loeffler, D. A., Camp, D. M., & Conant, S. B. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-29 · Cited by 150

The immune system in Parkinson's disease: what we know so far

Roodveldt, C., Bernardino, L. I., Çakmak, Ö. Ö., Dragić, M., Fladmark, K. E., Ertan, S., Aktaş, B., Pita, C., Ciglar, L., Garraux, G., et al. (2024) · Brain · doi:10.1093/brain/awae177 · Cited by 151

ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo

Barcia, C., Ros, C. M., Annese, V., Carrillo-de Sauvage, M. A., Ros-Bernal, F., Gómez, A., Yuste, J. E., Campuzano, C. M., de Pablos, V., Fernandez-Villalba, E., et al. (2012) · Scientific Reports · doi:10.1038/srep00809 · Cited by 150

Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells

Nagatsu, T., & Sawada, M. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_7 · Cited by 149

Microglial Implication in Parkinson’s Disease: Loss of Beneficial Physiological Roles or Gain of Inflammatory Functions?

Lecours, C., Bordeleau, M., Cantin, L., Parent, M., Paolo, T. D., & Tremblay, M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00282 · Cited by 148

Microglial conditioned medium promotes survival and development of cultured mesencephalic neurons from embryonic rat brain

Nagata, K., Takei, N., Nakajima, K., Saitō, H., & Kohsaka, S. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490340313 · Cited by 144

Toll-like receptors and their therapeutic potential in Parkinson’s disease and α-synucleinopathies

Kouli, A., Horne, C. B., & Williams-Gray, C. H. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.042 · Cited by 143

Time course of dopamine neuron loss and glial response in the 6‐ OHDA striatal mouse model of P arkinson's disease

Stott, S., & Barker, R. A. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12459 · Cited by 147

Expression of the histocompatibility glycoprotein HLA-DR in neurological disease

McGeer, P. L., Itagaki, S., & McGeer, E. G. (1988) · Acta Neuropathologica · doi:10.1007/bf00689592 · Cited by 420

HLA-DR reactive microglia in Parkinson's disease

Itagaki, S., McGeer, P. L., & McGeer, E. G. (1987) · Journal of Neuroimmunology · doi:10.1016/0165-5728(87)90252-9 · Cited by 5

Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR

McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791

Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain

Styren, S. D., Civin, W. H., & Rogers, J. (1990) · Experimental Neurology · doi:10.1016/0014-4886(90)90054-v · Cited by 191